

Date: May 7, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051
Scrip Symbol: SUVENPHAR

Sub: Press release regarding change in name of the Company

Dear Sir/ Madam,

We enclose herewith press release in connection with change in name of the Company from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited.

We request to take the aforesaid disclosure on your records.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: As above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com





Cohance Lifesciences, the new identity of Suven Pharmaceuticals

Hyderabad/Mumbai, May 7th, 2025

Suven Pharmaceuticals Limited, an integrated CDMO serving customers across the globe, has rebranded as **Cohance Lifesciences Limited**.

This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics.

The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.

"The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world " said Cohance Executive Chairman, Mr. Vivek Sharma.

The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals Limited” to “Cohance Lifesciences Limited”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation.

The Company would make necessary application to the BSE Limited and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and **the name “Suven Pharmaceuticals Limited” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences Limited”.**

-ENDS-

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

About Cohance Lifesciences (Formerly, Suven Pharmaceuticals Ltd):

Cohance Lifesciences is a leading technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. With over 100 active projects and a strong pipeline of late-stage molecules, Suven has built a reputation for delivering complex solutions at a scale with precision. Strengthening its technology expertise through strategic acquisitions—Sapala (June 2024) for oligonucleotides and NJ Bio for ADC technology (December 2024)—the platform (including Cohance lifesciences) has achieved consolidated revenue of US\$318 million (LTM, Dec24) while maintaining industry-leading margins and ROCEs over the past five years.

For more information, please contact:

Cyndrella Carvalho, Head - Investor Relations,

Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Ltd)

Tel: 040 2354 3311

Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com
rishab@cdr-india.com

Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999